Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cato Research, a global contract R&D organization, and Advanced Targeting Systems have announced a new strategic alliance focused on development and commercialization of SP-SAP for the treatment of chronic pain.
Subscribe to our email newsletter
Advanced Pain Therapeutics (APT), a new strategic development company formed by Cato Research, Advanced Targeting Systems (ATS), and Cato BioVentures, the venture capital affiliate of Cato Research, obtained exclusive, worldwide rights to develop, manufacture, use, and sell SP-SAP for the treatment of severe chronic pain. Cato Research will provide contract research organization services to the new company.
Denise Higgins, vice president of ATS, said: “We are enthusiastic about working with APT and Cato Research to help address the under-served chronic pain population. Our preclinical work with SP-SAP makes us very optimistic about the impact this innovative treatment can have for those who are suffering.”